Growth Autonomy 2 Flashcards
What are the members of the monomeric G proteins superfamily - Ras?
Rac
Rho
Rab
Arf
Example what each of these are in the biochemical, structural homology of HRas, Kras 4a & b and, NRas.
G domain
C terminla domain
CAAX region
- G domain: allows Ras proteins to act as monomeric gene proteins and contains death binding regions and various others so very conserved
- C terminal domain: very little conserved, lots divergence, equally proficient at driving cell cycle
- CAAX motif: localises Ras to membrane where it needs to be for its funcionality
Outline the Ras signalling cycle.
3 marks
- Ras when bound to GDP is inactive when bound to GTP in active conformation. Will switch itself off by hydrolysing 2GTP so back to inactive shape
- To cycle between conformations needs accessory proteins – guanine exchange factor (GEF) sos binds to ras and changes conformation to get rid of GTP and get GDP from cytosol
- Needs help with hydrolysis as have poor intrinsic GTPASE activity – hydrolysis is induced by GAP
Outline the molecular basis of the G protein conformational change
3 marks
- Binding of GTP crucial to conformational change
- On GDP - Two regions known as switch regions in protein so cant bind to any effector molecules – GDP
- Third phosphsate interacts with two highly conserved amino acids in switch region – causing massive conformational change in gene protein allowing it to interact with its effector e.g. pi3 kinase or raf
Which isoform of Ras is the most mutated and what does said mutation do?
- KRas mutations have the highest incidence and they render Ras constituitively active by preventing GTP hydrolysis
- Common point mutations alter AA residues at positions 12, 13 or 61
What are the hotspot mutations in Ras?
2 marks
AA 12 or 13 - point mutation here causes massive effect on activity of ras
How do mutations in Ras render it constitutively active?
By preventing GTP hydrolysis
How can Ras be inappropriately activated?
GAP deletion or mutation
GAP deletion:
- common GAP associated with RAS is neurofirbin
Mutation:
- mutations in neurofribrim gene NF1 cause dysregulated cell growth
Why is membrane localisation of ras important for its activity and how is it achieved?
4 marks
- Important to be able to receive signals
- Achieved by multi-step post-translational modifications
- First step: addition of isoprenoid lipid (farnesyl isoprenoid) to CAAX by farnesyl transferase
- Specified by variable region and CAAX motif
How does the post-translation modifications of Ras proteins take place?
7 marks
- 1st step occurs in cytosol and using substrate FFP enzyme farneyl transferasewill transfer farneysl onto csyteine of CAAX motif
- Using lipid farnesyl Ras will translocate and acnhor to outside of ER membrane
- Once anchored becomes substrate for enzyme Race which cleaves off 33 AA
- ICMT then methylesterifies the carboxyl group [on membrane as both race and ICMT exclusively located on membrane]
- Palmotiyl lipid group added by palmotyiltransferase onto Ras
- Using farneysl and palmitoyl group, Ras will anchor onto membrane
- ABOVE ONLY TRUE FOR NRAS, HRAS, KRAS4A
- Not for Kras4B has lycine rich region in variable region - can sub for palmitoyl bit so Kras4b doesn’t have palmitoyl group
What was seen in preclinical studies with farmesyl transferase inhbitors?
2 marks
- Significant potency as an ant-cancer drug for wide panel cancer cell lines
- Activity independent of Ras mutational status
What was seen in in vivo models of farnesyl transferase inhibitors?
2 marks
- Activity in xenograft tumours regardless of Ras mutation
- Little toxicity when combined with toxic drug
What was seen in clinical trials with FTIs?
1 marks
- Patients showed little to no response or ad some stability for very short period of time
Why did patients react in certain way in the clinical trials with FTIs?
3 marks
- Kras and Nras still being prenylated and localised from cells
- Only Hras was actually farnesylated
- Kras and Nras can be alternatively prenylated through addition of geranylgeranyl 20-carbon isprenoid moiety by GGTase
Why couldn’t an anti-cancer drug for Kras be used?
Drugs too toxic as knocking out too many proteins can’t be used in clinic